Cash Flow from Financial Activities: The net amount of cash transactions used in funding activities.
Enliven Therapeutics, Inc. (ELVN) had Cash Flow from Financial Activities of $473.47M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-32.48M |
|
-- |
|
-- |
|
$37.21M |
|
$-37.21M |
|
$4.72M |
|
$-32.48M |
|
$-32.48M |
|
$-32.48M |
|
$-32.48M |
|
$-32.48M |
|
$-32.48M |
|
$-37.21M |
|
$-36.69M |
|
66.17M |
|
66.17M |
|
$-0.49 |
|
$-0.49 |
|
| Balance Sheet Financials | |
$907.34M |
|
$0.14M |
|
$2.88M |
|
$910.22M |
|
$14.16M |
|
-- |
|
$0.91M |
|
$15.07M |
|
$895.15M |
|
$895.15M |
|
$895.15M |
|
73.25M |
|
| Cash Flow Statement Financials | |
$-37.82M |
|
$-399.04M |
|
|
Cash Flow from Financial Activities |
$473.47M |
$98.90M |
|
$135.50M |
|
$36.61M |
|
$21.31M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
64.07 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-37.92M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-3.63% |
|
-3.63% |
|
-3.57% |
|
-3.63% |
|
$12.22 |
|
$-0.57 |
|
$-0.57 |
|